- Pfizer and Valneva reported topline Phase 3 results for their experimental Lyme disease vaccine, showing over 70% efficacy but missing the primary statistical endpoint due to low case numbers.
- Pfizer still plans to pursue regulatory approval, pointing to confidence in the clinical profile of the candidate.
- The vaccine targets a disease that currently has no approved human vaccine and is part of Pfizer's shift toward a broader non COVID portfolio.
For investors tracking NYSE:PFE, this Lyme disease readout adds a fresh angle beyond the usual focus on existing therapeutics. The share price sits at $27.28, with a 1 year return of 16.1% and a 3 year return of an 18.8% decline, reflecting a mixed picture over different timeframes. In that context, a potential first in class vaccine can be relevant when you think about how the business mix is evolving.
What stands out here is Pfizer's decision to move ahead with regulators despite the missed primary endpoint, given the low number of Lyme cases in the study. With no current human vaccine for Lyme disease, investors may want to watch how agencies assess the data package and real world need. Any progress or setbacks in this process could influence how you frame Pfizer's efforts to broaden its non COVID revenue base.
Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer.
1 thing going right for Pfizer that this headline doesn't cover.
Quick Assessment
- ⚖️ Price vs Analyst Target: At $27.28, Pfizer trades about 4.6% below the $28.58 analyst target, which sits in the middle of a $25 to $36 range.
- ✅ Simply Wall St Valuation: Simply Wall St views the shares as undervalued, trading around 55.8% below its estimated fair value.
- ✅ Recent Momentum: The 30 day return of roughly 0.8% is modest, yet it keeps the price within reach of the analyst range while this vaccine story unfolds.
There is only one way to know the right time to buy, sell or hold Pfizer. Head to Simply Wall St's company report for the latest analysis of Pfizer's Fair Value.
Key Considerations
- 📊 Lyme vaccine progress supports Pfizer's effort to build out non COVID revenue sources, even though the trial missed its primary statistical endpoint.
- 📊 Watch for regulatory feedback, any follow up studies, and how much management highlights this asset compared with existing franchises.
- ⚠️ Major risks already flagged, including forecast EPS decline of 3.7% a year and a dividend that is not well covered by earnings or free cash flow, can matter if new products take time to contribute.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Pfizer analysis. Alternatively, you can check out the community page for Pfizer to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com